Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug24 | 1: Prone positioning Wiki | 0.33 |
| drug33 | 2: No instruction regarding positioning Wiki | 0.33 |
| drug3981 | muscle ultrasound Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1130 | ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB. Wiki | 0.33 |
| drug608 | CMR with T1 and T2 mapping Wiki | 0.33 |
| drug2466 | Performing routine care (clinical and paraclinical tests) Wiki | 0.33 |
| drug1229 | Examinations for the research: Wiki | 0.33 |
| drug1168 | Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care Wiki | 0.33 |
| drug3571 | Ultra Brief Online Mindfulness-based Intervention Wiki | 0.33 |
| drug3936 | laboratory biomarkers Wiki | 0.33 |
| drug2400 | PLX-PAD Wiki | 0.33 |
| drug2431 | Passed infection of SARS-CoV-2 Wiki | 0.33 |
| drug480 | Biological data Wiki | 0.24 |
| drug804 | Clinical data Wiki | 0.19 |
| drug881 | Control Wiki | 0.11 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018376 | Cardiovascular Abnormalities NIH | 0.33 |
| D009220 | Myositis NIH | 0.24 |
| D006330 | Heart Defects, Congenital NIH | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009203 | Myocardial Ischemia NIH | 0.16 |
| D054058 | Acute Coronary Syndrome NIH | 0.15 |
| D054556 | Venous Thromboembolism NIH | 0.13 |
| D007238 | Infarction NIH | 0.11 |
| D020246 | Venous Thrombosis NIH | 0.10 |
| D013923 | Thromboembolism NIH | 0.09 |
| D011655 | Pulmonary Embolism NIH | 0.09 |
| D004617 | Embolism NIH | 0.08 |
| D013927 | Thrombosis NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012819 | Myocarditis HPO | 0.94 |
| HP:0100614 | Myositis HPO | 0.33 |
| HP:0001627 | Abnormal heart morphology HPO | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.18 |
| HP:0002625 | Deep venous thrombosis HPO | 0.11 |
| HP:0002204 | Pulmonary embolism HPO | 0.09 |
| HP:0001907 | Thromboembolism HPO | 0.08 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.06 |
Navigate: Correlations HPO
There are 9 clinical trials
COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use. Other clinico-biological features predictive of mortality or transfer to Intensive Care Unit are also needed. Cases of myocarditis have also been reported with COVID-19. Cardio-vascular events have possibly been highly underestimated. The study proposes to systematically collect cardio-vascular data to study the incidence of myocarditis and coronaropathy events during COVID-19 infection.We will also assess predictive factors for transfer in Intensive Care Unit or death.
Description: Viral myocarditis or myocardial infarction or stenosis detected with ST segment elevation or depression associated with troponine elevation and transthoracic echocardiography
Measure: Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay Time: ECG and concomitant troponine at day 1 after admission at day 1, day 3 day 6 the first week after admission, and then at day 14 and before the patient is discharged (up to 20 days)Description: Cardio-vascular events including but not limited to: myocardial infarction or stenosis, stroke, pulmonary embolism, deep vein thrombosis, ventricular dysfunctio, conduction disorders and sudden death
Measure: Description of cardiovascular outcomes in the cohort Time: During hospital admission (up to 20 days)Description: Biological biomarkers including but not limited to: baseline troponine T, D-dimers, NT-proBNP, creatinine phosphokinase, creatininemia, ionogram, renine-angiotensin aldosterone system profiling, glycemia (fasting), HbA1c, steroid profiling, lipid profiling
Measure: Prognosis role of baseline cardio-vascular caracteristics on patients survival Time: 1st day of admissionDescription: Biological markers including but not limited to: C reactive protein, procalcitonine, fibrinogen, interleukin-6
Measure: Characterization of inflammation on cardio-vascular outcomes Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)Description: clinical features at baseline: WHO performans status comorbidities and treatments Biological markers including but not limited to: full blood count, C reactive protein, procalcitonine, fibrinogen, interleukin-6, troponin and brain natriuretic peptide
Measure: Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival Time: Baseline and at day 3 day 6 day 14 and before patient is discharged (up to 20 days)Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Measure: Determine the incidence of cardiomyopathies and venous thromboembolism Time: 28 daysDescription: Incidence of mortality at day 28
Measure: Mortality Time: 28 daysDescription: Number of day of using mechanical ventilation for each patients
Measure: Duration of mechanical ventilation Time: 28 daysDescription: Incidence of shock at day 28
Measure: shock at day 28 Time: 28 daysDescription: Number of day in intensive care unit
Measure: length of stay in the intensive care unit Time: 28 daysProspective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019 (Covid-19), who are admitted to the intensive care unit of the department of anesthesiology and intensive care medicine, or the department of neurology at Tübingen University Hospital.
Description: Elevation of creatine kinase during hyperacute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase in hyperacute phase Time: 1 weekDescription: Elevation of creatine kinase during hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of elevated creatine kinase Time: 24 monthsDescription: Two-peak elevation of creatine kinase during acute phase of corona virus disease 2019 (Covid-19)
Measure: Rate of two-peak elevation of creatine kinase during acute phase Time: 30 daysDescription: Presence of myositis-specific antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of myositis-specific antibodies Time: 24 monthsDescription: Presence of antimyocardial antibodies on admission, at two weeks, and at end of follow-up
Measure: Rate of antimyocardial antibodies Time: 24 monthsDescription: Level of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19) assessed by the area under the curve (AUC)
Measure: Area under the curve (AUC) of elevated creatine kinase Time: 24 monthsDescription: Maximal value of creatine kinase elevation in the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of elevated creatine kinase Time: 24 monthsDescription: Maximal value of troponin in the acute phase of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of troponin Time: 30 daysDescription: Maximal value of urine myoglobin in the acute of corona virus disease 2019 (Covid-19)
Measure: Peak-levels of urine myoglobin Time: 30 daysDescription: Muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Rate of muscle hyperechogenicity Time: 24 monthsDescription: Peak-muscle hyperechogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score) during the hyperacute, acute, subacute and chronic phase of corona virus disease 2019 (Covid-19)
Measure: Peak-muscle hyperechogenicity Time: 24 monthsTo date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.
Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.
Measure: Evolution of the proportion of positive SARS-COV-2 cases. Time: 6 months.Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion
Measure: Ultrasound characteristics. Time: 1 yearDescription: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.
Measure: Assess prognosis of the acute myocarditis . Time: The short-term (30 days) and long-term (1 year).Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)
Measure: The factors associated with acute myocarditis cases . Time: The short-term (30 days) and long-term (1 year).Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment CRP(mg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Ventricular volumes (ml)
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Systole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Diastole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of left ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of right ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of left ventricular oedema
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T2 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Perfusion anomalies
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of early left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of late left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 after contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Presence of a pericardial effusion
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearThe study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.
Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance
Measure: Myocarditis Time: up to 3 monthsDescription: Prevalence of pericarditis assessed by clinical criteria
Measure: Pericarditis Time: up to 3 monthsDescription: Prevalence of atrial fibrillation on EKG
Measure: Atrial fibrillation Time: up to 3 monthsDescription: Prevalence of ischemic heart disease assessed by cardiac magnetic resonance
Measure: Ischemic heart disease Time: up to 3 monthsDescription: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance
Measure: Dilatation of right heart chambers Time: up to 3 monthsDescription: Prevalence of valvular heart disease assessed by cardiac magnetic resonance
Measure: Valvular hear disease Time: up to 3 monthsDescription: Prevalence of prolonged QT interval on EKG
Measure: Rhythm disorders Time: up to 3 monthsThe study objectives are to descript clinical, biological and echocardiographic features of an acute myocarditis in children in the context of COVID-19 and to identify the underlying mechanism : direct viral damage and/or inadequate host response risk.
Description: Occurrence, description and time course of acute myocarditis
Measure: Acute myocarditis Time: 7 daysDescription: Occurrence, description and time course of multi-systemic inflammatory syndrome, features of Kawasaki disease
Measure: Multi-systemic inflammatory syndrome Time: 7 daysDescription: Occurrence, description and time course of features of Kawasaki disease
Measure: Kawasaki disease Time: 7 daysDescription: Results of SARS-CoV-2 screening either by PCR or antibodies serological assay
Measure: Results of SARS-CoV-2 Time: 7 daysMagnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy and prognostic relationships in apparently healthy subjects with no known heart disease. A further unknown relates to separation between healthy myocardium and the subclinical disease in several groups of patients with suspected cardiac involvement. Examples include patients with systemic inflammatory conditions, as well as patients with a recent COVID-19 infection.
Description: number of deaths
Measure: All-cause mortality Time: 1 yearDescription: number of deaths
Measure: All-cause mortality Time: 5 yearsDescription: Number of participants with events including death due to heart failure and and hospitalisation due to Heart Failure
Measure: Heart Failure Outcome Time: 1 year and 5 yearsDescription: Number of participants with death due to myocardial infarction, heart failure, arrhythmia or vascular events (pulmonary embolism, aortic dissection, stroke)
Measure: Cardiovascular Outcome Time: 1 year and 5 yearsDescription: Number of participants with documented events including sudden cardiac death, appropriate ICD discharge, sustained VT
Measure: Arrhythmia Outcome Time: 1 year and 5 yearsMyocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.
Description: Myocardtitis diagnosis in patients COVID+ and troponin+
Measure: characterize the myocardial damage associated with CoV-2 SARS infection Time: Through study completion, an average of 1 yearPresentation, Clinical Course and Patterns of Myocardial Damage due to Viral Myocarditis
Description: All patients admitted with symptoms , signs and echocardiographic finding suggesting myocarditis within 3 months from start of the symptoms. as acute heart failure, arrhythmias, typical chest pain with ST segment deviation in ECG . dilated cardiomyopathy associated with normal Coronary Angiography, history of upper respiratory tract infection within the last 3 months. All will be investigated for determine the pattern of viral myocarditis in those patients
Measure: Determine the pattern of myocarditis in hospitalized patients with acute HF within the last 3 months Time: 6 monthsDescription: 1. Determine the pattern of broad spectrum cardiotropic viruses in patients with acute HF within the last 3 months. These viruses like enteroviruses, adenoviruses and parvo B19 virus, HBV, HCV and Covid 19 virus due to its increased prevelance nowadays.
Measure: determination of the caustive organism Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports